Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder

被引：33

作者：

Barton, J ^{[1
]}

机构：

[1] Staffordshire Combined Hlth Care NHS Trust, Abbey Hulton Clin, Moorlands Team, Stoke On Trent ST2 8BP, Staffs, England

来源：

ARCHIVES OF DISEASE IN CHILDHOOD | 2005年 / 90卷

关键词：

D O I：

10.1136/adc.2004.059386

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Atomoxetine is a novel, non-stimulant, highly selective noradrenaline reuptake inhibitor that has been studied for use in the treatment of attention deficit/hyperactivity disorder (ADHD). Data from clinical trials show it to be well tolerated and effective in the treatment of ADHD in children, adolescents, and adults. Improvements were seen not only in core symptoms of ADHD, but also in broader social and family functioning and self esteem. Once-daily dosing of atomoxetine has been shown to be effective in providing continuous symptom relief. Atomoxetine does not appear to have abuse potential and is associated with a benign side effect profile. The development of atomoxetine thus represents an important advance in the pharmacological management of ADHD.

引用

页码：I26 / I29

页数：4

共 43 条

[21] Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder [J].

Kratochvil, CJ ;

Vaughan, BS ;

Harrington, MJ ;

Burke, WJ .

EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (07) :1165-1174

[22] Atomoxetine and methylphenidate treatment in children with ADHD: A prospective, randomized, open-label trial [J].

Kratochvil, CJ ;

Heiligenstein, JH ;

Dittmann, R ;

Spencer, TJ ;

Biederman, J ;

Wernicke, J ;

Newcorn, JH ;

Casat, C ;

Milton, D ;

Michelson, D .

JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2002, 41 (07) :776-784

[23]

LANDGRAF JM, 1996, CHILD HTLH QUESTIONN

[24] Adult psychiatric status of hyperactive boys grown up [J].

Mannuzza, S ;

Klein, RG ;

Bessler, A ;

Malloy, P ;

LaPadula, M .

AMERICAN JOURNAL OF PSYCHIATRY, 1998, 155 (04) :493-498

[25]

MCCRACKEN JT, 2003, 50 ANN M AM AC CHILD

[26] Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study [J].

Michelson, D ;

Allen, AJ ;

Busner, J ;

Casat, C ;

Dunn, D ;

Kratochvil, C ;

Newcorn, J ;

Sallee, FR ;

Sangal, RB ;

Saylor, K ;

West, S ;

Kelsey, D ;

Wernicke, J ;

Trapp, NJ ;

Harder, D .

AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (11) :1896-1901

[27] Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies [J].

Michelson, D ;

Adler, L ;

Spencer, T ;

Reimherr, FW ;

West, SA ;

Allen, AJ ;

Kelsey, D ;

Wernicke, J ;

Dietrich, A ;

Milton, D .

BIOLOGICAL PSYCHIATRY, 2003, 53 (02) :112-120

[28] Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study [J].

Michelson, D ;

Faries, D ;

Wernicke, J ;

Kelsey, D ;

Kendrick, K ;

Sallee, FR ;

Spencer, T .

PEDIATRICS, 2001, 108 (05) :E83

[29]

SANGAL RB, 2004, ASS PROF SLEEP SOC M

[30] Atomoxetine hydrochloride: Clinical drug-drug interaction prediction and outcome [J].

Sauer, JM ;

Long, AJ ;

Ring, B ;

Gillespie, JS ;

Sanburn, NP ;

DeSante, KA ;

Petullo, D ;

VandenBranden, MR ;

Jensen, CB ;

Wrighton, SA ;

Smith, BP ;

Read, HA ;

Witcher, JW .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 308 (02) :410-418

← 1 2 3 4 5 →